InflaRx Hosts R&D Event Highlighting the Promise of INF904

Core Insights - InflaRx N.V. is advancing its oral small molecule C5aR inhibitor, INF904, targeting chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) as part of its immuno-dermatology development strategy [1][4][10] Company Overview - InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics, utilizing proprietary technologies to develop inhibitors of the complement activation factor C5a and its receptor C5aR [12] - The company was founded in 2007 and has operations in Germany and the USA [12] Product Development - INF904 is designed to inhibit C5a-induced signaling and has shown promise in pre-clinical models for its anti-inflammatory effects [11] - The company plans to initiate a Phase 2a basket trial for INF904 by the end of 2024, involving 75 patients with moderate-to-severe CSU and HS [5][6] - The trial will assess safety, pharmacokinetics (PK), and preliminary efficacy over a 4-week treatment period, with data expected in summer 2025 [6][8] Clinical Trial Design - The CSU group will include 45 patients randomized to receive INF904 at doses of 30 mg and 90 mg twice daily [7] - Efficacy measures for CSU will include changes in Urticaria Activity Score 7 (UAS7) and other patient-reported outcomes [7] - The HS group will consist of 30 patients receiving doses of 30 mg, 60 mg, or 90 mg twice daily, with similar efficacy measures [9] Market Potential - The commercial assessment indicates that CSU and HS represent multi-billion-dollar market opportunities, highlighting a significant unmet medical need for effective treatments [8][10] - INF904 is viewed as a "pipeline-in-a-product," with potential applications extending beyond immuno-dermatology to areas such as nephrology, neurology, and hematology [10] Financial Position - InflaRx's strong financial position is expected to support operations and clinical program advancements into 2026 [8]